middle.news
How Nexsen’s $8M IPO Fuels Breakthrough Kidney and GBS Diagnostics
11:42am on Friday 31st of October, 2025 AEDT
•
Healthcare
Read Story
How Nexsen’s $8M IPO Fuels Breakthrough Kidney and GBS Diagnostics
11:42am on Friday 31st of October, 2025 AEDT
Key Points
Completed $8 million IPO and ASX listing at a premium
Received $0.64 million R&D Tax Incentive funding
Advanced kidney function diagnostic tests with RMIT University
Commenced clinical trials for GBS Rapid Sensor in October 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nexsen (ASX:NXN)
OPEN ARTICLE